We are a medical startup company founded in Kyoto in 2018 with the goal of bringing a therapeutic drug for intractable cancer to society. We are researching cancer treatment technologies and creating cancer diagnostic and therapeutic drugs so that we can help patients suffering from cancer as soon as possible.CORPORATE
We aim to realize a new anti-cancer drug with L-glucose bound Orbio-molecules. We deliver the hope of complete cure beyond the diversity of intractable cancer.
We will implement “cancer-specific cell therapy” using L-glucose as a drug delivery system (DDS), which shows unprecedented high selectivity in cancer treatment.
Professor Emeritus, Kyoto University
Visiting Professor, Ritsumeikan University
Doctor of Science
Vice-President of The Japan Academic Society for Ventures and Entrepreneurs
Lecturer, the Graduate School of Medicine, Hirosaki University
Doctor of Engineering
Ph.D. in Management of Innovative Management
ORBIO-Chaired Professor, Department of Molecular Transport, Hirosaki University Graduate School of Medicine
Visiting Professor, Osaka Metropolitan University Graduate School of Medicine
Ph.D. in Medicine; Councilor of the Physiological Society of Japan
Master of Commerce
Dr. Yamada, CMO, Gave an Invited Lecture at Rare Sugar Congress 2023
Dr. Yamaguchi, CEO, Pitched at Japan-UK Virtual Partnering Event
CEO, Dr. Yamaguchi Pitching at Minerva Business Plan Presentation
We have renewed our website.
Requested Lecture: “Ascites fluid cytology using fluorescently labeled L-glucose compound 2-NBDLG”